References
- Bae, S.-J., J.-H. Oum, S. Sharma, J. Park, and S.-W. Lee. 2002. In vitro selection of specific RNA inhibitors of NFATc. Biochem. Biophys. Res. Commun. 298: 486-492 https://doi.org/10.1016/S0006-291X(02)02490-7
- Behrens, S.-E., L. Tomei, and R. De Francesco. 1996. Identification and properties of the RNA-dependent RNA polymerase of the hepatitis C virus. EMBO J. 15: 12-22
- Biroccio, A., J. Hamm, I. Incitti, R. De Francesco, and L. Tomei. 2002. Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 76: 3688-3696 https://doi.org/10.1128/JVI.76.8.3688-3696.2002
- Burgstaller, P., A. Girod, and M. Blind. 2002. Aptamers as tools for target prioritization and lead identification. Drug Discov. Today 7: 1221-1228 https://doi.org/10.1016/S1359-6446(02)02522-9
- Cload, S. T., T. G. McCauley, A. D. Keefe, J. M. Healy, and C. Wilson. 2006. Properties of therapeutic aptamers, pp. 363-416. In S. Klussmann (ed.). The Aptamer Handbook. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
- De Francesco, R. 1999. Molecular virology of the hepatitis C virus. J. Hepatol. 312: 47-53
- Ellington, A. D. and J. W. Szostak. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822 https://doi.org/10.1038/346818a0
- Gold, L., P. Allen, J. Binkley, D. Brown, D. Schneider, S. R. Eddy, C. Tuerk, L. Green, S. Macdougal, and D. Tasset. 1993. RNA: The shape of things to come, pp. 497-510. In: R. F. Gestelend and J. F. Atkins (eds.). The RNA World. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y
- Hwang, B., K. Han, and S. W. Lee. 2003. Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer. FEBS Lett. 548: 85-89 https://doi.org/10.1016/S0014-5793(03)00745-2
- Hwang, B., J. S. Cho, H. J. Yeo, J.-H. Kim, K. M. Chung, K. Han, S. K. Jang, and S.-W. Lee. 2004. Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA 10: 1277-1290 https://doi.org/10.1261/rna.7100904
- Hwang, B. and S.-W. Lee. 2005. Analysis of in vivo interaction of HCV NS3 protein and specific RNA aptamer with yeast three-hybrid system. J. Microbiol. Biotechnol. 15: 660-664
- Krieger, N., V. Lohmann, and R. Bartenschlager. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75: 4614-4624 https://doi.org/10.1128/JVI.75.10.4614-4624.2001
- Kumar, P. K., K. Machida, P. T. Urvil, N. Kakiuchi, D. Vishnuvardhan, K. Shimotohno, K. Taira, and S. Nishikawa. 1997. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 237: 270-282 https://doi.org/10.1006/viro.1997.8773
- Lauer, G. M. and B. D. Walker. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345: 41-52 https://doi.org/10.1056/NEJM200107053450107
- Lee, S. W. and B. Sullenger. 1996. Isolation of a nuclease resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. J. Exp. Med. 194: 315-324
- Lee, S. W. and B. Sullenger. 1997. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nature Biotechnol. 15: 41-45 https://doi.org/10.1038/nbt0197-41
- Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113 https://doi.org/10.1126/science.285.5424.110
- Moradpour, D., V. Brass, R. Gosert, B.Wolk, and H. Blum. 2002. Hepatitis C: Molecular virology and antiviral targets. Trends Mol. Med. 8: 476-482 https://doi.org/10.1016/S1471-4914(02)02395-X
- Ng, E. W. M., D. T. Shima, P. Calias, E. T. Cunningham Jr., D. R. Guyer, and A. P. Adamis. 2006. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Rev. Drug Discov. 5: 123-132 https://doi.org/10.1038/nrd1955
- Nishikawa, F., N. Kakiuchi, K. Funaji, K. Fukuda, S. Sekiya, and S. Nishikawa. 2003. Inhibition of HCV NS3 protease by RNA aptamers in cells. Nucleic Acids Res. 31: 1935-1943 https://doi.org/10.1093/nar/gkg291
- Pagratis, N. C., C. Bell, Y. F. Chang, S. Jennings, T. Fitzwater, D. Jellinek, and C. Dang. 1997. Potent 2'-amino, and 2'-fluoro-2'deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nature Biotechnol. 15: 68-73 https://doi.org/10.1038/nbt0197-68
- Park, C.-H., Y.-H. Kee, J.-H. Lee, J.-H. Oh, J.-C. Park, and H.-J. Myung. 1999. Purification and characterization of recombinant hepatitis C virus replicase. J. Microbiol. Biotechnol. 9: 881-884
- Purcell, R. 1997. The hepatitis C virus: Overview. Hepatology 26(Suppl 1): S11-S14 https://doi.org/10.1002/hep.510260702
- Rusconi, C. P., J. D. Roberts, G. A. Pitoc, S. M. Nimjee, R. R. White, G. Jr. Quick, E. Scardino, W. P. Fay, and B. A. Sullenger. 2004. Antidote-mediated control of an anticoagulant aptamer in vivo. Nature Biotechnol. 22: 1423-1428 https://doi.org/10.1038/nbt1023
- Seo, H. S. and S. W. Lee. 2000. In vitro selection of the 2'-fluoro-2'-deoxyribonucleotide decoy RNA inhibitor of myasthenic autoantibodies. J. Microbiol. Biotechnol. 10: 707-713
- Sullenger, B. A. and E. Gilboa. 2002. Emerging clinical applications of RNA. Nature 418: 252-258 https://doi.org/10.1038/418252a
- Thiel, K. 2004. Oligo oligarch - the surprisingly small world of aptamers. Nat. Biotechnol. 22: 649-651 https://doi.org/10.1038/nbt0604-649
- Tuerk, C. and L. Gold. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510 https://doi.org/10.1126/science.2200121
- Vo, N. V., J. W. Oh, and M. M. Lai. 2003. Identification of RNA ligands that bind hepatitis C virus polymerase selectively and inhibit its RNA synthesis from the natural viral RNA templates. Virology 307: 301-316 https://doi.org/10.1016/S0042-6822(02)00095-8
- Zuker, M. 2003. Mfold Web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31: 3406-3415 https://doi.org/10.1093/nar/gkg595